NASDAQ:EOLS - Evolus Stock Price, Forecast & News

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Tuesday, February, 25th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.38. The firm had revenue of $19.45 million for the quarter, compared to analyst estimates of $18.93 million. View Evolus' Earnings History.

Evolus is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Evolus.

Evolus issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $31.8 million.

10 brokers have issued twelve-month target prices for Evolus' shares. Their forecasts range from $9.00 to $35.00. On average, they expect Evolus' share price to reach $25.40 in the next year. This suggests a possible upside of 202.7% from the stock's current price. View Analyst Price Targets for Evolus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.

News stories about EOLS stock have trended very negative on Friday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evolus earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Evolus.

Evolus saw a increase in short interest in February. As of February 14th, there was short interest totalling 7,520,000 shares, an increase of 14.6% from the January 30th total of 6,560,000 shares. Based on an average daily volume of 632,100 shares, the days-to-cover ratio is presently 11.9 days. Approximately 34.0% of the company's shares are short sold. View Evolus' Current Options Chain.

Some companies that are related to Evolus include Y-mAbs Therapeutics (YMAB), Zogenix (ZGNX), Amneal Pharmaceuticals (AMRX), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), I-Mab (ARQT), Dermira (DERM), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Akebia Therapeutics (AKBA), Portola Pharmaceuticals (PTLA) and Athenex (ATNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA), Canopy Growth (CGC) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus' stock is owned by a number of of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (7.88%), EcoR1 Capital LLC (1.80%), Cadian Capital Management LP (1.52%), Goldman Sachs Group Inc. (1.44%), State Street Corp (0.89%) and Geode Capital Management LLC (0.87%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View Institutional Ownership Trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Raymond James Financial Services Advisors Inc., Bank of America Corp DE, B. Riley Wealth Management Inc., Advisor Group Inc., Victory Capital Management Inc., Victory Capital Management Inc. and Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Corp Alphaeon, Lauren P Silvernail and Rui Avelar. View Insider Buying and Selling for Evolus.

EOLS stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, EcoR1 Capital LLC, Goldman Sachs Group Inc., Point72 Asset Management L.P., Cadian Capital Management LP, Voss Capital LLC, State Street Corp and Geode Capital Management LLC. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank and Vikram Malik. View Insider Buying and Selling for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $8.39.

Evolus has a market capitalization of $282.99 million and generates $34.92 million in revenue each year. The company earns $-46,870,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.View Additional Information About Evolus.

The official website for Evolus is http://www.evolus.com/.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]